Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nelson Lekeayi Acha has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Sequencing Identifies SNPs Associated with Antimalarial Drug Resistance and the CSP Vaccine Antigen in Plasmodium falciparum from Southwest Cameroon

    by Mary T. Efeti, Sandra N. Fankem, Mariama T. Diallo, Methodius S. Lahngong, Nelson L. Acha, Robert A. Shey, Kristiaan Demeyer, Jacob Souopgui, Stephen M. Ghogomu, Rose Njemini

    Malaria is a major public health challenge in low- and middle-income countries with significant socio-economic impacts. While chemotherapy has greatly contributed to malaria control, the widespread emergence of resistance to antimalarial drugs threatens progress towards elimination goals. In parallel, the recent rollout of the RTS,S/AS01 and R21/Matrix-M malaria vaccine—targeting the Plasmodium falciparum circumsporozoite protein (CSP)—offers a new prevention tool but may be influenced by parasite genetic diversity. This study investigated the genetic architecture of Plasmodium falciparum circulating in a community in the Southwest Region of Cameroon. Seventy-two blood samples were analyzed using targeted Oxford Nanopore sequencing of pfcrt, pfmdr1, pfdhfr, pfdhps, pfkelch13 and pfcsp genes. We observed a high prevalence of pfdhfr mutations (98.6% N51I, 98.6% C59R, 97.7% S108N) and pfmdr1 Y184F (76.1%) mutation. Mutations in pfdhps (54.2% S436A, 2.8% A437G, 38.9% A581G) were also observed. No WHO-validated pfkelch13 artemisinin resistance markers were found; however, K189T (63.4%) and R255K (4.2%) variants were detected. Nineteen non-synonymous SNPs were identified in pfcsp, reflecting natural background variations as vaccination status was not known. These findings support the continued use of artemisinin-based combination therapies and underscores the need for sustained molecular surveillance of both antimalarial drug resistance and vaccine-related polymorphisms, to inform malaria control strategies.


  • Open Access

    In silico design and computational characterization of novel chimeric multiepitope antigens for Mpox serosurveillance

    by Stephen Ghogomu, Roland Ngwese Akwelle, Robert Adamu Shey, Mary Efeti Teke, Nelson Lekeayi Acha, Gordon Takop Nchanji, Tangan Yanick Aqua Stong, Joan Amban Chick, Emmaculate Yaah Ntang, Cabirou Mounchili Shintouo, et al.

    Background The Monkeypox (Mpox) virus is a zoonotic Orthopoxvirus with a global outbreak that began in 2022 and spread to more than 128 countries, with more than 132,000 confirmed cases and 1500 deaths. The pandemic preparedness pipeline emphasizes the importance of diagnostic surveillance of pathogens in at-risk populations to monitor transmission and mitigate the impact on public health. Unfortunately, the current gold standard diagnostic tool for Mpox is limited in its field applicability. Therefore, there is a crucial need for the development of robust novel diagnostic tools to enable continuous surveillance of the disease. As such, this work sought to design and validate novel multiepitope antigens as diagnostic tools for Mpox serosurveillance. Methods Using immunoinformatic approaches, two novel Mpox multiepitope antigens (MP-MEDA-1 and MP-MEDA-2) were designed using linear B-epitopes of viral proteins previously characterized in Mpox serodiagnosis. The 3D structures of the designed antigens were predicted, refined, and validated. Protein-protein docking and interaction analyses were performed between the designed diagnostic antigens and the Fab regions of human IgA, IgG, and IgM. Results The designed antigens were predicted to be antigenic and demonstrated thermostability with desirable physicochemical properties. In addition, both antigens also demonstrated stable interactions with the Fab regions of selected immunoglobulins, with several residues interacting at the interfaces of all the docked complexes. Conclusions These preliminary findings highlight the potential of the MP-MEDA-1 and MP-MEDA-2 antigens as candidates to be further characterized for Mpox serosurveillance. The next phase of this project will focus on the expression and serological characterization of both antigens to determine their diagnostic parameters (sensitivity, specificity, and others).